ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Nasdaq: ARWR · Pasadena, CA · Healthcare
$71.05+1.80 (+2.60%)Closed
Market Cap$9.76B
Cash$69.4Mmost recent
Runwayprofitable
P/E (TTM)—EPS $-0.01
52-Wk Range$12.36 – $73.00
Avg Volume2.4M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$71.05+197.0%
Pipeline
Drug candidates sponsored by ARROWHEAD PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Plozasiran Injection | Hypertriglyceridemia+1 more | Recruiting | 2026-05 | 4 | |
| Phase 3 | zodasiran Injection | Homozygous Familial Hypercholesterolemia | Recruiting | 2027-08-20 | 1 | |
| Phase 3 | Zodasiran | Homozygous Familial Hypercholesterolemia | Not yet recruiting | 2028-07 | 1 | |
| Phase 3 | Plozasiran | Familial Chylomicronemia+2 more | Recruiting | 2029-03 | 3 | |
| Phase 2 | ARC-AAT Injection | Alpha-1 Antitrypsin Deficiency | Terminated | 2016-11past | 2 | |
| Phase 2 | ARC-520 Injection | Chronic Hepatitis B+1 more | Terminated | 2017-01past | 3 | |
| Phase 2 | ARC-520 | Hepatitis B+4 more | Completed | 2017-01past | 6 | |
| Phase 1 | ARO-HBV | Hepatitis B | Completed | 2020-04-23past | 1 | |
| Phase 1 | ARO-ENaC | Cystic Fibrosis, Pulmonary | Terminated | 2021-05-09past | 1 | |
| Phase 1 | ARO-HSD Injection | Non-alcoholic Steatohepatitis | Completed | 2021-09-03past | 1 | |
| Phase 2 | Fazisiran Injection | Alpha 1-Antitrypsin Deficiency | Completed | 2021-11-08past | 1 | |
| Phase 2 | ARO-AAT | Alpha 1-Antitrypsin Deficiency | Completed | 2022-04-28past | 1 | |
| Phase 2 | ARO-ANG3 | Mixed Dyslipidemia+3 more | Completed | 2022-08-30past | 2 | |
| Phase 2 | ARO-ANG 3 Injection | Homozygous Familial Hypercholesterolemia | Active, not recruiting | 2023-05-02past | 1 | |
| Phase 1 | ARO-MUC5AC | Asthma+1 more | Terminated | 2024-11-12past | 1 | |
| Phase 1 | ARO-C3 | C3 Glomerulopathy+1 more | Completed | 2025-05-05past | 1 | |
| Phase 1 | ARO-MMP7 Inhalation Solution | Idiopathic Pulmonary Fibrosis | Completed | 2025-09-05past | 1 | |
| Phase 2 | ARO-APOC3 | Mixed Dyslipidemia+4 more | Completed | 2025-09-18past | 4 | |
| Phase 1 | ARO-INHBE | Obesity | Recruiting | 2026-05 | 1 | |
| Phase 1 | ARO-DIMERPA | Hyperlipidemia; Mixed | Recruiting | 2026-06 | 1 | |
| Phase 1 | ARO-ALK7 | Obesity+1 more | Recruiting | 2026-10 | 1 | |
| Phase 1 | ARO-DM1 Intravenous (IV) Infusion | Myotonic Dystrophy 1 | Recruiting | 2026-12 | 1 | |
| Phase 1 | ARO-DUX4 for Injection | Facio-Scapulo-Humeral Dystrophy | Recruiting | 2026-12 | 1 | |
| Phase 1 | ARO-MAPT-SC | Alzheimer Disease+1 more | Recruiting | 2027-06 | 1 | |
| Phase 1 | ARO-RAGE | Asthma | Recruiting | 2027-12 | 2 | |
| Phase 1 | ARC-521 Injection | Hepatitis B | Terminated | 2016-11past | 1 | |
| Phase 1 | ARO-AAT Injection | Alpha 1-Antitrypsin Deficiency | Completed | 2018-10-23past | 1 | |
| Phase 1 | ARO-HIF2 | Clear Cell Renal Cell Carcinoma | Completed | 2022-01-24past | 1 | |
| Phase 1 | ARO-RAGE Injection | Asthma | Completed | 2024-02-08past | 1 | |
| Phase 1 | ARO-SOD1 Injection | Amyotrophic Lateral Sclerosis | Withdrawn | 2025-03past | 1 | |
| Phase 1 | ARO-CFB | IgA Nephropathy | Active, not recruiting | 2025-03-31past | 1 | |
| Phase 1 | ARO-ATXN2 Injection | Spinocerebellar Ataxia Type 2 | Recruiting | 2026-12 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for ARWR. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.